Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Stressgen (VSE: SSB) -- Ignore unavailable to you. Want to Upgrade?

To: Heat Shock who wrote (157)	3/15/2001 7:18:49 PM
From: Heat Shock	Read Replies (1) \| Respond to of 236

To all: conference call notes, hastily scribbled: anal dysplasia PIII trial expected to complete enrollment this year. Then they consider "different pathways to filing", whatever that may be. They have half of the 128 needed (5 centres). one of the Stressgen people was delighted at the success of HspE7 (hispy seven) in genital warts. Genital warts was not an original indication but was added later after some trial results for the other indications became available. Apparently, in order to work against genital warts, a therapy has to be effective against a number of the dozens of Human Papillomavirus subtypes. This is possibly due to Stressgen's use of "full length antigens". cervical cancer trial to run in Brazil, where cervical cancer is a huge problem. burn is to be around 3 million a month. in Feb01 Stressgen met with a bunch of virologists to evaluate the numerous Stressgen product candidates in indications like HIV/AIDS (HspP24), Herpes Simplex Virus, and Hepatitis B. Chronic hepatitis B infection was chosen as the probable next product candidate to go to trials. Unmet medical need and other factors. 20Mar01 someone from National Jewish in Denver is going to present some results of heat shock protein alone being used in asthma on the AIDS front, Stressgen has produced an SIV heat shock fusion protein to test with. They have an anti-HIV product already (HspP24). Stressgen has over 70 patents pending Stressgen's patents are of the type "composition of matter and analogues thereof". The "heat shock protein fusion technology" links the full length antigen covalently to the heat shock protein to produce a single protein molecule which can be perfectly described. Antigenics (AGEN) uses stress proteins also, but their business is a service model where they provide a service and do not sell a product. Their patents are of a methodology type. They said Antigenics was not a competitor and they hoped they do great so as to give publicity to stress proteins. Antigenics has a therapy against some viral condition, but it has an super-short antigen protein fragment non-covalently joined with a heat shock protein. This is likely to be effective against only one subtype of the virus. Stressgen has product candidates made for infections of type viral, bacterial and fungal. CEO Dan Korpolinski said Stressgen wanted to wait as long as possible to partner its product candidates so as to get the best possible deal. The company's cash will last 2 years longer with no partnering. new San Diego office to provide access to tons of biotech resources in the area- lawyers, support services, etc. the Collegeville office near Philadelphia is for corporate headquarters and is near the 2 CROs Stressgen uses for clinical trial help and manufacturing help. Heat.